Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pairs two molecules that bring different mechanisms of action to suppressing HIV.
The post FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral appeared first on MedCity News.
